MedPath

MAPREG

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:2
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

Phase 2
Active, not recruiting
Conditions
Depression
Interventions
Drug: Placebo
First Posted Date
2019-03-12
Last Posted Date
2024-09-30
Lead Sponsor
Mapreg
Target Recruit Count
110
Registration Number
NCT03870776
Locations
🇫🇷

CHU Angers, Angers, France

🇫🇷

CHU Besançon, Besançon, France

🇫🇷

CHD Vendée, La Roche-sur-Yon, France

and more 7 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.